BR112018073553A2 - medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. - Google Patents

medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.

Info

Publication number
BR112018073553A2
BR112018073553A2 BR112018073553-1A BR112018073553A BR112018073553A2 BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2 BR 112018073553 A BR112018073553 A BR 112018073553A BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2
Authority
BR
Brazil
Prior art keywords
fibromyalgia
symptoms associated
pharmaceutical composition
functional symptoms
preventing
Prior art date
Application number
BR112018073553-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jae JO Min
Ju Yi Han
Gwan Hwang Sun
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of BR112018073553A2 publication Critical patent/BR112018073553A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112018073553-1A 2016-05-19 2017-05-18 medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. BR112018073553A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
BR112018073553A2 true BR112018073553A2 (pt) 2019-03-19

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073553-1A BR112018073553A2 (pt) 2016-05-19 2017-05-18 medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.

Country Status (14)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
CA (1) CA3024286A1 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086076B2 (ja) * 2016-12-14 2022-06-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用
KR102739580B1 (ko) * 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
AU2019361856B2 (en) * 2018-10-19 2024-11-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
US20230000763A1 (en) * 2019-11-22 2023-01-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
IL159846A0 (en) * 2001-07-16 2004-06-20 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2765566C (en) * 2009-06-22 2016-04-12 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии

Also Published As

Publication number Publication date
KR20170131242A (ko) 2017-11-29
EP3459543A4 (en) 2020-01-15
AU2017265839A1 (en) 2018-12-13
EP3459543A1 (en) 2019-03-27
CN109475529B (zh) 2022-02-22
JP7071287B2 (ja) 2022-05-18
AU2017265839B2 (en) 2022-10-27
MX2018014080A (es) 2019-04-04
US20190298694A1 (en) 2019-10-03
US10849882B2 (en) 2020-12-01
RU2018144785A (ru) 2020-06-19
JP2019516707A (ja) 2019-06-20
WO2017200318A1 (ko) 2017-11-23
RU2753525C2 (ru) 2021-08-17
PL3459543T3 (pl) 2023-04-11
RU2018144785A3 (enExample) 2020-08-11
ES2935596T3 (es) 2023-03-08
MX394245B (es) 2025-03-19
CN109475529A (zh) 2019-03-15
CA3024286A1 (en) 2017-11-23
DK3459543T3 (da) 2023-02-13
KR102489052B1 (ko) 2023-01-16
EP3459543B1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]